

# Comparative genome sequencing of *Escherichia coli* allows observation of bacterial evolution on a laboratory timescale

Christopher D Herring<sup>1,6,7</sup>, Anu Raghunathan<sup>1,6,7</sup>, Christiane Honisch<sup>2,7</sup>, Trina Patel<sup>1</sup>, M Kenyon Applebee<sup>3</sup>, Andrew R Joyce<sup>2</sup>, Thomas J Albert<sup>4</sup>, Frederick R Blattner<sup>5</sup>, Dirk van den Boom<sup>2</sup>, Charles R Cantor<sup>2</sup> & Bernhard Ø Palsson<sup>1</sup>

**We applied whole-genome resequencing of *Escherichia coli* to monitor the acquisition and fixation of mutations that conveyed a selective growth advantage during adaptation to a glycerol-based growth medium. We identified 13 different *de novo* mutations in five different *E. coli* strains and monitored their fixation over a 44-d period of adaptation. We obtained proof that the observed spontaneous mutations were responsible for improved fitness by creating single, double and triple site-directed mutants that had growth rates matching those of the evolved strains. The success of this new genome-scale approach indicates that real-time evolution studies will now be practical in a wide variety of contexts.**

Comparative genomics has been almost entirely focused on genomic changes over long periods of time, on the order of millions of years. A new microarray-based method of whole-genome resequencing called comparative genome sequencing (CGS)<sup>1</sup> now makes it cost efficient to monitor bacterial evolution comprehensively over short time periods as well. This capability is important because many microbial phenomena, such as the emergence of new pathogens and the acquisition of antibiotic resistance factors, can occur over relatively short time scales. Experimental evolution of bacteria and viruses<sup>2,3</sup> is a facile approach to study these topics. It has been used to test predictions of evolutionary theory<sup>4</sup> and to study parallel changes in populations evolved for 20,000 generations<sup>5</sup>, acquisition of antibiotic resistance<sup>1</sup> and *in vitro* symbiosis<sup>6</sup>. Our laboratory has used experimental evolution as a tool for metabolic engineering<sup>7</sup> and to study the recovery of strains with gene knockouts in central metabolic genes<sup>8</sup>. Nevertheless, much remains unknown about genome plasticity over short evolutionary timescales.

It is a common mistake to think of bacteria as static; that is, to assume that a culture grown overnight is the same as it was the day before. It has been estimated that nearly 10% of the individual bacteria in a *Salmonella enterica* population carry large-scale genome rearrangements<sup>9</sup>, and in a suboptimal environment, selection can alter a population very rapidly. The 10–20 generations that occur in the process of growing a bacterial culture are sufficient to create a heterogeneous population, depending on the magnitude of the

selective advantage of adaptive mutations. This problem is avoided by using strains of bacteria that are adapted to common laboratory media, but there are interesting cases where a seemingly straightforward growth medium poses a great challenge to a bacterium.

An example is *E. coli* K-12 grown in minimal medium supplemented with glycerol as the carbon and energy source. Despite a complete pathway for glycerol catabolism, large variations in the growth rates of various strains have been noted<sup>10</sup>. Growth of the sequenced strain MG1655 has been observed to differ from computational predictions based on flux balance analysis<sup>11</sup>. Upon extended logarithmic growth in glycerol minimal medium, the growth rate is observed to increase from  $\mu = 0.22 \text{ h}^{-1}$  to  $\mu = 0.55 \text{ h}^{-1}$  in as few as 20 d ( $\sim 223$  generations) and is observed to reach the computationally predicted optimum.

The goals of the current study were to determine the genetic basis of the adaptation to glycerol minimal medium and to observe the dynamic behavior of the mutations identified. We chose five populations of *E. coli* that were cultured in continuous logarithmic growth in glycerol minimal medium. Gene expression studies of these populations have been performed previously but have not uncovered the underlying basis of adaptation<sup>12</sup>. We have previously reported the results of resequencing 4.4% of the genomes of these populations using mass spectrometry<sup>13</sup>. In the current study, we have performed comprehensive resequencing of these strains, evaluated the effects of mutations both genetically and biochemically and monitored their occurrence within the populations.

<sup>1</sup>Department of Bioengineering, <sup>2</sup>Bioinformatics Program and <sup>3</sup>Department of Chemistry and Biochemistry, University of California, San Diego, California 92093, USA. <sup>4</sup>Nimblegen Systems, Inc., Madison, Wisconsin 53711, USA. <sup>5</sup>Laboratory of Genetics, University of Wisconsin, Madison, Wisconsin 53706, USA. <sup>6</sup>Current addresses: Mascoma Corporation, Lebanon, New Hampshire 03766, USA (C.D.H.); Division of Infectious Diseases, Mt. Sinai School of Medicine, New York, New York, 10029, USA (A.R.). <sup>7</sup>These authors contributed equally to this work. Correspondence should be addressed to B.Ø.P. (bpalsson@bioeng.ucsd.edu).

Received 23 June; accepted 21 September; published online 5 November 2006; doi:10.1038/ng1906

**Table 1 Validated mutations in clones isolated after 44 d of experimental evolution**

Clone	Gene	Product or function	Mutation	Gene position (in nucleotides)	Region	Genome position
GB-1	<i>glpK</i>	Glycerol kinase	A → T	218	Coding	4115028
	<i>rpoC</i>	RNA polymerase β'	Deletion, 27 bp	3132..3158	Coding	4186504..4186530
GC-1	<i>glpK</i>	Glycerol kinase	G → T	184	Coding	4115062
	<i>n/a</i>	All genes between <i>insC</i> -5 and <i>insD</i> -6	Duplication, 1313 kb <sup>a</sup>	<i>n/a</i>	<i>n/a</i>	~3189209..4497523
GD-1	<i>glpK</i>	Glycerol kinase	G → A	816	Coding	4114430
	<i>rpoB</i>	RNA polymerase β	A → T	1685	Coding	4180952
	<i>murE</i>	Peptidoglycan biosynthesis	A → C	8	Coding	93173
GE-1	<i>glpK</i>	Glycerol kinase	A → C	113	Coding	4115133
	<i>rpoC</i>	RNA polymerase β'	C → T	2249	Coding	4185621
	<i>dapF</i>	Lysine/peptidoglycan biosynthesis	C → A	512	Coding	3993293
G2-1	<i>glpK</i>	Glycerol kinase	Duplication, 9 bp	705	Coding	4114541
	<i>rph-pyrE</i>	RNase PH; pyrimidine synthesis	Deletion, 82 bp	<i>rph</i> : 610..end	Coding + intergenic	3813882..3813963
	<i>pdxK-crr</i>	Pyridoxal kinase; enzyme IIa glucose	Deletion, 28 bp	<i>pdxK</i> : 833..end	Coding + intergenic	2534400..2534427

<sup>a</sup>Evident in CGS mapping data; not independently validated.

## RESULTS

### Comparative genome sequencing

We isolated individual clones after 44 d of growth in glycerol minimal medium (~660 generations) from each of five populations, named GB, GC, GD, GE and G2. Genomic DNA was isolated and hybridized to microarrays by Nimblegen Systems, Inc. using their CGS strategy<sup>1</sup>. A total of 95 putative SNPs were reported by Nimblegen in the five clones. Each putative SNP was checked by PCR amplification and sequencing using MassARRAY SNP discovery (Sequenom) and reconfirmed by Sanger sequencing if detected. Out of 95 reported SNPs, 17 were confirmed (one false positive per 297 kb). Of the confirmed mutations, nine were resolved as sequence differences at three loci between the sequenced strain of MG1655 and the strain used to start the experimental evolution (see Methods).

In addition to identifying the SNPs, Nimblegen provided the location of probes that showed a difference between the test and reference samples on mapping arrays but that showed inconclusive results on the sequencing arrays. From this data, we chose 15 regions for PCR amplification and Sanger sequencing, selecting regions where multiple nearby probes were implicated. This process led to the identification of three deletions. In addition, we identified a probable duplication in clone GC-1 of a 1,313-kb region that included the replication origin between two copies of the mobile genetic element IS2 (b3044 and b4273). All confirmed mutations are listed in **Table 1**.


Mobile genetic elements, particularly insertion sequence (IS) elements, excise from and insert into genomic DNA at relatively high frequency. Their movement is one of the most common types of genetic changes and is considered an important factor in evolution<sup>14</sup>. The *E. coli* MG1655 genome contains seven different IS elements (26 total copies); the most prevalent are IS1 and IS5. To check for the movement of these IS elements, we probed DNA blots of *FspI*-digested genomic DNA from wild-type bacteria and from clones G1-1, G2-1, GA-1 and GD-1 with IS1 and IS5 DNA. The pattern of bands matched the pattern calculated from the reference genome sequence except for copy #5 of IS1 (b1894), which was deleted in all strains and their wild-type progenitor. The deletion was confirmed by PCR amplification using primers adjacent to IS1-5. This loss of IS1-5 is consistent with an independent resequencing project<sup>6</sup> and high rates of activity noted previously at this locus<sup>15</sup>.

MassARRAY SNP discovery and Sanger sequencing of candidate genes representing ~7% of the genome uncovered two additional mutations that were not detected by the microarrays, including a 9-bp

duplication in *glpK* and a 28-bp deletion of the 3' end of *pdxK* and part of the downstream transcriptional terminator in clone G2-1. It seems likely that the strong secondary structure of the terminator led to the failure to detect the *pdxK* deletion with CGS. A total of 1.5% of the *E. coli* genome consists of predicted intrinsic terminator sequences (computed using data from <http://cbcb.umd.edu/software/transerm/>; C. Kingsford, personal communication). Nimblegen estimates the rate of false negative detection of single nucleotide substitutions to be 5%. The error rates for the detection of deletions and insertions on the low-resolution mapping arrays is not known.

### Analysis of mutations

To evaluate the contributions of individual mutations to increased growth rate in glycerol minimal medium, we introduced each



**Figure 1** Growth rates of site-directed mutants. For each mutant, the names of the mutated genes are given, and in parentheses, the population from which the mutation was identified. The growth rate increase was calculated as the increase in growth rate of the mutant over the wild-type divided by the increase in growth rate of the endpoint clone over the wild-type. Error bars indicate s.d. Additional details are presented in **Supplementary Table 3**.

**Table 2 Biochemical measurements of mutant glycerol kinase**

Mutation	Source population	Amino acid change	Location	$V_{max}$ ( $\mu\text{mol glycerol min}^{-1} \text{mg}^{-1}$ ) (% increase over WT)	$K_{i\text{-FBP}}$ (mM)
WT				15.8	0.5
A218T	GB	D73V	Interface of subunit interaction	36 (128%)	>2
G184T	GC	V62L	Interface of subunit interaction	29.8 (89%)	>2
G816A	GD	M272I	Uncharacterized	36.9 (134%)	>2
A113C	GE	Q38P	EII <sup>Glc</sup> interaction helix	23.9 (51%)	0.5
G692A	G1	G231D	FBP binding loop	27.3 (73%)	>2
Ins 9 bp	G2	Insert KGG	FBP binding loop	29.8 (89%)	>2

WT, wild-type.

mutation into the wild-type strain using a site-directed mutagenesis strategy called gene gorging<sup>16</sup>. Growth rate measurements (Fig. 1) showed that mutations in genes encoding the two major subunits of RNA polymerase (*rpoB* and *rpoC*) conferred the largest change in growth rate, representing 48%–65% of the total change. Mutations in *glpK* and *pdxK* also had significant effects. The 82-bp deletion in *rph* probably relieves pyrimidine starvation documented in MG1655 caused by a frameshift mutation in *rph*<sup>17</sup>, but its effect on growth rate was undetectable. Competition experiments are a more sensitive means to measure relative fitness and may be used to investigate such mutations with small effects.


In addition to creating single mutants, we also made double and triple mutants to reconstruct the clones isolated after experimental evolution. The growth rates of four such reconstruction strains matched the growth rates of the evolved clones of which they were reconstructions (GB-1, G2-1, GE-1 and GD-1). This indicates that we were able to identify all of the important mutations in these clones and that there was not any epigenetic component to the adaptation to glycerol minimal medium. On the other hand, the growth rate of one strain did not match that of the corresponding evolved clone GC-1. Sanger sequencing of ten likely candidate genes did not uncover any other mutations. It seems probable that the 1,313-kb genomic rearrangement in this strain (which we did not attempt to reconstruct) either contributes to the growth rate or masks the presence of mutations in the duplicated region. Many of the genes implicated in this study (*glpK*, *rpoB*, *rpoC* and *cyaA*) are located in the duplicated region and may carry heterozygous mutations not detected by CGS or Sanger sequencing.

All clones had mutations in the gene for glycerol kinase (*glpK*), which catalyzes the first step in glycerol catabolism. This protein is subject to inhibition by fructose-1,6-bisphosphate (FBP) and unphosphorylated enzyme IIA<sup>Glc</sup> (ref. 18). Partially purified protein from cells expressing the mutant genes encoding these enzymes showed reaction rates 51%–133% higher than wild-type, and five showed reduced inhibition by FBP (Table 2). As all glycerol-adapted populations

have mutations in *glpK*, rapid growth on glycerol can be partially attributed to altered kinetic and regulatory properties of glycerol kinase. Evidently, the rate of glycerol phosphorylation catalyzed by GlpK limits the rate of growth of wild-type *E. coli* MG1655 (ref. 19). The glycerol catabolic pathway generates the glycolytic intermediate dihydroxyacetone phosphate, which can be converted to methylglyoxal, a toxic metabolite when present at high concentrations<sup>10,20</sup>. It is noteworthy that we did not detect mutations in any genes relating to methylglyoxal metabolism.

We identified mutations in genes involved in peptidoglycan biosynthesis (*murE* and *dapF*) in two different clones. DapF produces the metabolite meso-2,6-diaminopimelate, whereas MurE consumes it. It is unclear what advantage these mutations confer, as site-directed mutations in these genes had negligible effects. The only exception was the *glpK rpoB murE* triple mutant, which grew faster than the *glpK rpoB* double mutant. To the best of our knowledge, there is no relationship between *murE* or *dapF* mutations and glycerol metabolism. As the mutations occurred after RNA polymerase mutations were fixed (Fig. 2), they might compensate for some detrimental side effect of RNA polymerase mutations.

The gene *pdxK* encodes pyridoxine kinase, involved in vitamin B6 salvage. As there is no direct connection between *pdxK* and glycerol metabolism, it is interesting to note that *pdxK* is adjacent to *crr*,



**Figure 2** Allele frequency estimation (AFE). The prevalence of mutations in each population was measured over the course of experimental evolution using hME genotyping and MassARRAY (Sequenom). The mutant alleles are denoted by different symbols. The average maximum error over all replicate measurements using MassEXTEND biochemistry was 0.015 and thus too small to be meaningfully represented with error bars. The lower right panel shows the growth rates of the evolving populations over time.

encoding enzyme IIA<sup>Glc</sup>, a regulator of glycerol kinase and a critical component in catabolite repression<sup>21</sup>. The deletion at the 3' end of *pdxK* results in deletion of part of a terminator between the convergently transcribed genes *pdxK* and *crr* and might be able to attenuate enzyme IIA<sup>Glc</sup> expression through some interesting mechanism, such as antisense inhibition.

Clone G1-1 carries a mutation in *cyaA*, encoding another key player in catabolite repression, adenylate cyclase. The 5-bp deletion near the 3' end of *cyaA* is likely to result in a truncated protein. It has been previously reported that a similarly truncated mutant of adenylate cyclase had lower activity and was not repressed by glycerol-3-phosphate<sup>22</sup>. We hypothesize that wild-type strain MG1655 grows slowly on glycerol because some critical genes are misexpressed as a result of inappropriate levels of catabolite repression and that the attenuating mutations in *cyaA* and *pdxK/crr* relieve this misexpression.

Thus, much of the increase in growth rate seems to be achieved by a transcriptional adjustment. The clones GB-1, GD-1 and GE-1 may accomplish the same effect through mutations in the genes encoding RNA polymerase. It is possible that the RNA polymerase mutations affect the level of catabolite repression by affecting RNA polymerase interactions with catabolite activator protein CAP, but this explanation seems unlikely because CAP interacts with the  $\alpha$  subunit of RNA polymerase, whereas the mutations are in the genes encoding the  $\beta$  and  $\beta'$  subunits<sup>23</sup>. Another hypothesis is that the RNA polymerase mutations achieve a beneficial transcriptional adjustment by affecting some other regulatory aspect, such as inhibition by guanosine tetraphosphate (ppGpp), transcriptional pausing or anti-termination. Few transcriptional commonalities were identified between the evolved populations in a previous expression study<sup>12</sup>, but that previous study looked only for commonalities present in six of the seven populations. Knowing the mutations that the populations share now allows us to analyze the expression data more productively. Looking just at data from the populations with mutations in the genes encoding RNA polymerase (GA, GB, GD, GE), we found that there were 672 ORFs with statistically significant changes in gene expression in common, using wild-type cells grown in glycerol as the reference. These ORFs had a significant overrepresentation of the following functional categories: cell motility, acid resistance and stationary phase (which were downregulated) as well as protein processing and ribosome structure (which were upregulated). Hierarchical clustering of expression data from all populations showed that GA, GB, GD and GE grouped into one clade (Supplementary Fig. 1 online).

### Mutation frequencies in evolving populations

We monitored the fixation of mutations identified in endpoint clones using allele frequency estimation (AFE) (Fig. 2 and Supplementary Table 1 online). We collected samples of the evolving populations and froze them at regular intervals. Genomic DNAs from the revived samples were PCR amplified, and oligonucleotides adjacent to the mutations were extended and then quantitated using mass spectrometry, validating and calibrating each assay with artificial DNA mixtures. This technique has a limit of detection of 2% (ref. 24). In general, the dynamic behavior followed the same pattern: mutations were undetectable in early time points and then became fixed over 4–20 d. Mutations with large fitness effects (*glpK* or *rpoBC* mutations) were fixed first and more quickly relative to mutations with small effects (*dapF*, *murE*, and *rph* mutations), as expected. An exception was the *pdxK* mutation in population G2, which occurred only in the last two time points, consistent with the slow rise in growth rate of this population (Fig. 2, lower right panel).

**Table 3 Genotypes of individual colonies isolated after 15 d of experimental evolution**

Population	Number of colonies	Genotype	Outcome <sup>a</sup>
GB	95	<i>glpK</i> -A218T <i>rpoC</i> -del27	Endpoint
GC	96	<i>glpK</i> -G184T	Endpoint
GD	100	<i>glpK</i> -G816A <i>rpoB</i> -A1685T	Endpoint
	6	<i>glpK</i> -A172C	Transient
	4	<i>glpK</i> -A218T	Transient
GE	77	<i>glpK</i> -A113C <i>rpoC</i> -C2249T	Endpoint
	12	<i>glpK</i> -G22T	Transient
	7	<i>glpK</i> -G217T <i>rpoC</i> -C2249T	Transient

<sup>a</sup>Whether the indicated mutations persisted (endpoint) or were lost (transient).

In GB, the *rpoC* mutation became detectable 4 d before the *glpK* mutation, although both mutations became fixed simultaneously at day 10, suggesting that the addition of the *glpK* mutation allowed the *rpoC* mutants to overcome competitors. Similarly, the *rpoB* and *glpK* mutations in population GD seem to have been fixed simultaneously. The *glpK* and *rpoC* mutations in GE also seem to have been fixed simultaneously, although the *glpK* mutation later decreased unexpectedly. This decrease may have been due to the rise of a fitter *rpoC glpK* combination (as discussed in the next paragraph) that was then outcompeted when the *dapF* mutation occurred. Overall, AFE results are consistent with the magnitude of fitness effects observed with site-directed mutagenesis and provide detailed insight into population dynamics.

These results show the histories of the evolutionary 'winners' in the populations but do not show alternate genotypes that may have been important in the outcome of the experiment. In order to observe alternate clonal lineages and to assess the amount of variation present during the course of experimental evolution, we sequenced candidate genes in individual clones isolated from the evolving populations at day 15. For strains GB, GC, GD and GE, regions of ~500 bp surrounding each endpoint mutation were resequenced using Mass ARRAY SNP discovery (Sequenom) to identify alternate alleles in important genes (Table 3). We identified four alternate *glpK* alleles in GD and GE but none in the others. Surprisingly, two of the alternate alleles (A218T and G217T) affected the same amino acid (Asp73) as the A218T mutation in clone GB-1. A mutation in this amino acid was identified in a previous study<sup>25</sup> and was shown to decrease inhibition by FBP and the formation of inactive tetramers. For the A218T mutation in GD, we were able to rule out cross-contamination because the accompanying *rpoC* mutation from GB was not present in GD colonies. AFE analysis showed the transient occurrence of this allele in GD (Fig. 2). In GE, we observed the *rpoC*-C2249T allele present in the endpoint in four colonies together with a *glpK* allele that was not present in the endpoint clone. This suggests that the *rpoC*-C2249T allele occurred before the *glpK* alleles, in agreement with AFE results, and supports our explanation of the temporary decrease in the frequency of *glpK*-A113C.

Colony genotyping results were consistent with AFE results in all respects except for the frequency of the *rpoB* mutation in GD, which was 88% in colonies and 33% in AFE. This quantitative discrepancy can be explained by colony picking bias for large colonies, as the AFE assay was calibrated with artificial control mixtures. We measured growth rates of individual clones, but the variation in growth rates seemed to be less than the noise in growth rate measurements, making it impossible to correlate growth rates with individual genotypes.

## DISCUSSION

The genetic investigation of experimental evolution can uncover mechanisms of evolution and new connections between genotype and phenotype. Recently developed methods such as CGS now allow this investigation on a genomic scale, yielding insightful results when gene expression data may be difficult to interpret. This study has demonstrated the efficacy of genome resequencing and site-directed mutagenesis for the detection and analysis of adaptive mutations. Our results demonstrate that marked changes in phenotype can be mediated by as few as two mutations, in concordance with results in *Saccharomyces cerevisiae*, maize and the influenza virus<sup>26–28</sup>. Reconstruction of the evolved clones using mutagenesis completely accounted for the phenotypic change in four out of five cases. Additionally, we used AFE to observe the dynamic behavior of mutations as they were fixed and identified transient alleles that were lost from evolving populations.

Whole-genome resequencing is now a cost-effective tool for the study of experimental bacterial evolution. The cost of CGS resequencing services from Nimblegen Systems is currently \$7,500 per clone for *E. coli*. This cost may be less for smaller genomes or if Nimblegen increases the density of probes on their arrays. The cost of verifying 30 putative mutations is ~\$800. The accuracy of CGS relative to other methods such as polony technology<sup>6</sup> or sequencing by synthesis<sup>29</sup> has not been evaluated.

CGS is designed for the identification of SNPs, but we identified deletions and a large-scale duplication as well. The mutations with the largest effects occurred in the genes encoding glycerol kinase and RNA polymerase. We did not detect any mutations fixed by genetic hitchhiking (that is, the fixation of mutations by their occurrence in the same clone as a beneficial mutation). This lack of hitchhiking is presumably due to low rates of spontaneous mutation, possibly attributable to avoiding nutrient depletion (that is, stationary phase) during adaptation. As the growth rate increased, the population that was passaged each day of experimental evolution decreased from ~10<sup>7</sup> at the outset to ~10<sup>3</sup> cells after 44 d. We cannot calculate mutation rates from our data because we do not know the total number of mutations that occurred—only the number that were fixed. For populations that fixed three mutations, the rate of fixation was  $1.8 \times 10^{-11}$  per genome per generation, taking into account the population size and number of generations on each day of evolution. If we assume  $2.0 \times 10^{-9}$  beneficial mutations per genome per generation<sup>30</sup>, then only about 1 out of every 100 beneficial mutations was fixed.

One of the most notable questions that this study begins to address is why wild-type *E. coli* K-12 is maladapted to growth on glycerol minimal medium despite a complete metabolic pathway for the substrate. Part of the explanation seems to be inappropriate levels of allosteric inhibition of glycerol kinase by FBP. This tight control is present in wild-type strains to avoid the toxic accumulation of methylglyoxal<sup>10</sup>. Another part of the explanation seems to be that the transcriptional program during growth in glycerol is not optimal and can be improved by mutations in the genes encoding RNA polymerase or in genes involved in catabolite repression. We have observed that some of the glycerol-adapted clones and site-directed mutants show growth defects in rich medium (data not shown). Evolutionary trade-offs between stress tolerance and metabolic capability have been previously associated with levels of the stationary-phase sigma factor *rpoS* (ref. 31). It may be that *E. coli* strain MG1655 has been adapted over the past 80 years by cultivation in rich medium at the expense of optimal use of glycerol.

Now that the key genes have been identified, the adaptation of *E. coli* to glycerol may prove to be an excellent model for the study of clonal interference and other evolutionary phenomena. The most influential mutations identified fall into two classes: those affecting a specific function (such as the rate-limiting enzyme GlpK) and those affecting global transcription patterns. Future work will show whether this reflects general principles of adaptation or if there are other important strategies for optimizing metabolism. A full appreciation of the plasticity of genomes<sup>32,33</sup> and the capacity of bacteria to rapidly adapt to new environments will emerge as genome-scale technologies such as CGS are applied to study experimental evolution.

## METHODS

**Experimental evolution.** A derivative of *E. coli* strain, K-12 MG1655 (ATCC #47076), was used for all experimental evolution cultures (see strain notes, below). The strains analyzed were generated as previously described<sup>12</sup>. Briefly, cells were grown in 250 ml M9 minimal medium + 0.2% glycerol in 500-ml Erlenmeyer flasks at 30 °C using a stir bar for aeration for 44 d (average 662 generations; see **Supplementary Table 2** online). Every day, optical density (OD) measurements were made and cells were diluted into fresh medium, estimating the amount of inoculum to use such that the culture would not enter stationary phase. Samples were frozen at days 2, 4, 6, 8, 10, 15, 20, 25, 30, 35, 40 and 44.

**Strain notes.** The different evolving populations were designated G1, G2, GA, GB, GC, GD and GE. In a previous study<sup>12</sup>, these populations were designated Gly1, Gly2, GlyA, etc. In another study<sup>11</sup>, the populations G1 and G2 were designated E1 and E2. Clones isolated as colonies from the endpoint populations (day 44) are designated by a clone number (such as G1-1, G2-1, GA-1, etc.). In a different study<sup>13</sup>, clones G1-1 and G2-1 were designated G1-A and G2-A. Site-directed mutants are all designated with strain names that begin with the initials BOP (**Supplementary Table 3** online).

A total of seven clones from different experimentally evolved populations were subjected to CGS (G1-1, G2-1, GA-1, GB-1, GC-1, GD-1 and GE-1). Clone GA-1 was found to contain the same two mutations as clone GB-1. AFE results indicated that the two mutations in clone GB-1 were detectable in population GA from day 30 onward but did not reach complete fixation. The two mutations had nearly identical frequencies in GA, suggesting that GB may have contaminated GA between days 25 and 30. It should be noted, however, that substitutions at nucleotide 218 of *glpK* and deletions near nucleotide 3140 of *rpoC* have been repeatedly isolated in glycerol evolution experiments (A.R.J., B.Ø.P., unpublished results).

Clone G1-1 was found to have five SNPs, two deletions and a 139-kb duplication (**Supplementary Table 4** online). This population was apparently started from a different strain from the others; it is wild-type for *hisC*, *btuE* and *ydaC*, but the others have mutations in these genes (see below). G1 was one of the first adaptive evolution experiments performed in our laboratory, and no frozen stock was saved from day 0 (the earliest saved was from day 6). In a preliminary AFE experiment, we found that the *aldB*, *rpoS* and *ybhF* mutations were present at 100% at day 6, supporting the notion that G1 was begun from a different starting strain. Because of uncertainty with G1-1, these results were not included in the main body of this study. The mutations present in G1-1 are listed in **Supplementary Table 4**, including a 1-bp deletion between *rph* and *pyrE* that was not detected by CGS (a false negative). The results of mutagenesis experiments with some of those mutations are presented in **Supplementary Table 3**.

The genome sequence of the strain used to inoculate the evolved populations GA, GB, GC, GD, GE and G2 differs from the genome sequence of *E. coli* strain MG1655 at three loci: *btuE*, *hisC* and *ydaC* (**Supplementary Table 5** online). The evolved population G1 does not have these mutations. The original ancestral strain was MG1655 (ATCC #47076), which does not have these three mutations. Evidently, the three mutations were acquired during early handling of the strain after the G1 experiment was performed and before the other evolutions. These facts were discovered during the course of resequencing the evolved clones. During mutation validation, we noticed that some putative mutations indicated by Nimblegen (*btuE*, *hisC* and *ydaC*) were present in more

than one clone. These mutations were confirmed in the starting strain by PCR amplification and Sanger sequencing. The CGS ‘mapping’ arrays detect hybridization differences between an experimental and a reference DNA. It is interesting that differences between the sequence on the chips and the reference DNA were also detected. These indications of differences were present only some of the time; the *btuE* deletion was indicated in ‘non-called regions of interest’ data for three clones and in the SNP results for one clone out of seven; the *hisC* mutation was indicated in SNP results for five clones and the *ydaC* mutation was indicated in the SNP results for three clones out of seven.

**Resequencing.** Genomic DNA was prepared from endpoint clones using the DNeasy Tissue Kit (Qiagen), followed by ethanol precipitation before submission to Nimblegen Systems for CGS<sup>1</sup>. Endpoint clones GA-1 and G1-1 were resequenced first, using the m54 release of the *E. coli* K-12 MG1655 genome sequence (GenBank accession number NC\_00096). The m56 release, which included 255 sequence corrections and the addition of 454 bp to the total genome length, was used for resequencing endpoint clones G2-1, GB-1, GD-1, GC-1 and GE-1. Putative deletions were identified from data from the first step of CGS (‘mapping’ arrays). Data provided by Nimblegen listed ‘non-called regions of interest’ (a list of probes that showed a hybridization difference between the reference and experimental samples for which no base call could be made). When two of these probes occurred within 100 bp of each other, they were flagged for further investigation. Seventeen of these flagged regions were investigated using PCR amplification and Sanger sequencing (for primers, see **Supplementary Table 6** online). In cases in which a deletion was verified, the same region was amplified and sequenced in other endpoint clones, which resulted in the identification of an additional deletion not detected by the microarrays, the 1-bp deletion between *rph* and *pyrE* in G1-1 (see strain notes, above). The deletion of IS1 copy #5 was evident in ‘non-called region of interest’ data from endpoint clones G2-A, GB-1 and GD-1 but not in G1-1, GA-1, GC-1 and GE-1.

**Mutation validation.** Oligonucleotide primer design around each putative SNP and MassARRAY SNP Discovery (Sequenom) was performed as described in ref. 13. Primers are listed in **Supplementary Table 6**. Briefly, the 500- to 700-bp PCR products were subjected to *in vitro* transcription, base-specific cleavage and analysis using MALDI-TOF mass spectrometry. The confirmed mutations were then PCR amplified and genotyped by MassARRAY hME (Sequenom) or sequenced with conventional Sanger sequencing for additional confirmation.

**Mutagenesis.** Each verified mutation was introduced into the WT strain using a method called ‘gene gorging’<sup>16</sup>. This method introduces any desired mutation without direct selection, and therefore leaves no antibiotic resistance gene or other trace of having been used. Details about mutagenesis and growth rate measurements can be found in **Supplementary Methods** online.

**Biochemical measurements.** The wild-type and mutant alleles of the *glpK* gene were amplified by PCR and cloned into pCRT7/NT-TOPO according to the manufacturer’s instructions (Invitrogen). Potential clones were checked for the presence of the correct insert in the correct orientation by restriction enzyme analysis, followed by Sanger sequencing. Protein overexpression was induced with isopropyl-β-D-thiogalactoside (IPTG). Cell-free extracts were prepared and glycerol kinase was purified using Amicon Ultra-15 size exclusion filters (Millipore), retaining the fraction between 50 kDa and 100 kDa. A sample was SDS-PAGE purified, and the 56-kDa band was cut out and analyzed with a combination of MALDI-TOF and Tandem mass spectrometry to confirm the sequence of GlpK. Enzymatic activity was measured as outlined in ref. 34. The activity of glycerol kinase was measured in the forward direction by monitoring ADP release at 340 nm by coupling pyruvate kinase and lactate dehydrogenase activity. A calibration curve was obtained using enzyme standards and chemicals purchased from Sigma Chemicals.

**Allele frequency estimation by matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) mass spectrometry.** Relative frequencies of mutant and corresponding wild-type alleles at different time points of evolution were determined by analysis of MassEXTEND primer extension products and MassCLEAVE products generated from amplified genomic DNA<sup>35</sup>. Details are provided in **Supplementary Methods**.

**Analysis of clones at day 15.** Frozen glycerol stocks from day 15 of each evolving population were struck on plates containing M9 minimal medium plus glycerol. Colonies were inoculated into liquid M9 glycerol medium and grown overnight at 30 °C. Glycerol stocks were prepared from each culture, and DNA preparations were prepared using the DNeasy Tissue kit (Qiagen). Using primers listed in **Supplementary Table 6**, MassARRAY SNP Discovery (Sequenom) was performed as above for SNP validation, except that only the reverse RNA strand was processed in most cases. This reduced the workload but resulted in ambiguous results for 48 out of 398 clones, almost all of which were resolved by Sanger sequencing. The PCR products that were screened for mutations were those that contained mutations in clones at the endpoint. Growth rates of individual colonies revived from frozen stocks were measured in 96 × 200 μl format in M9 minimal medium + 0.2% glycerol using a Versamax shaking plate reader (Molecular Devices) at 30 °C. Growth rates of selected colonies were also measured in 250-ml volumes of M9 glycerol medium.

*Note: Supplementary information is available on the Nature Genetics website.*

#### ACKNOWLEDGMENTS

We thank A. Fiest and S. Fong for useful discussions and M. Mosko, B. Groff and A. Maggay for technical contributions. These studies were supported by a grant from the US National Institutes of Health (NIH) (GM62791). C.D.H. was supported by NIH grant 1F32GM074590-01.

#### AUTHOR CONTRIBUTIONS

C.D.H. wrote the final manuscript, compiled and analyzed all final data, identified the deletions, made the site-directed mutants and measured their growth rates. A.R. initiated, designed and led work related to data acquisition, validation, analysis and interpretation of CGS data, cloning and biochemical characterization of *glpK* variants, day 15 colony analysis and AFE and drafted an earlier version of the manuscript. C.H. initiated, performed, analyzed and led the work relating to mass spectrometry; conceived of using mass spectrometry to confirm CGS results and using AFE on evolving populations; and wrote portions of the manuscript. T.P. verified results from CGS, performed day 15 colony analysis and AFE and assisted with other efforts. M.K.A. measured growth rates of clones from day 15 and site-directed mutants and performed day 15 colony analysis. A.R.J. performed analysis of gene expression data.

#### COMPETING INTERESTS STATEMENT

The authors declare competing financial interests (see the *Nature Genetics* website for details).

Published online at <http://www.nature.com/naturegenetics>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

1. Albert, T.J. *et al.* Mutation discovery in bacterial genomes: metronidazole resistance in *Helicobacter pylori*. *Nat. Methods* **2**, 951–953 (2005).
2. Elena, S.F. & Lenski, R.E. Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. *Nat. Rev. Genet.* **4**, 457–469 (2003).
3. Wichman, H.A., Badgett, M.R., Scott, L.A., Boulianne, C.M. & Bull, J.J. Different trajectories of parallel evolution during viral adaptation. *Science* **285**, 422–424 (1999).
4. Rokyta, D.R., Joyce, P., Caudle, S.B. & Wichman, H.A. An empirical test of the mutational landscape model of adaptation using a single-stranded DNA virus. *Nat. Genet.* **37**, 441–444 (2005).
5. Pelosi, L. *et al.* Parallel changes in global protein profiles during long-term experimental evolution in *Escherichia coli*. *Genetics* **173**, 1851–1869 (2006).
6. Shendure, J. *et al.* Accurate multiplex polony sequencing of an evolved bacterial genome. *Science* **309**, 1728–1732 (2005).
7. Fong, S.S. *et al.* *In silico* design and adaptive evolution of *Escherichia coli* for production of lactic acid. *Biotechnol. Bioeng.* **91**, 643–648 (2005).
8. Fong, S.S. & Palsson, B.O. Metabolic gene deletion strains of *Escherichia coli* evolve to computationally predicted growth phenotypes. *Nat. Genet.* **36**, 1056–1058 (2004).
9. Roth, J.R. *et al.* Rearrangements of the bacterial chromosome: formation and applications. in *Escherichia coli and Salmonella: Cellular and Molecular Biology* (ed. Neidhardt, F.C.) 2256–2276 (ASM Press, Washington D.C., 1996).
10. Lin, E.C. Glycerol dissimilation and its regulation in bacteria. *Annu. Rev. Microbiol.* **30**, 535–578 (1976).
11. Ibarra, R.U., Edwards, J.S. & Palsson, B.O. *Escherichia coli* K-12 undergoes adaptive evolution to achieve *in silico* predicted optimal growth. *Nature* **420**, 186–189 (2002).

12. Fong, S.S., Joyce, A.R. & Palsson, B.O. Parallel adaptive evolution cultures of *Escherichia coli* lead to convergent growth phenotypes with different gene expression states. *Genome Res.* **15**, 1365–1372 (2005).
13. Honisch, C., Raghunathan, A., Cantor, C.R., Palsson, B.O. & van den Boom, D. High-throughput mutation detection underlying adaptive evolution of *Escherichia coli*-K12. *Genome Res.* **14**, 2495–2502 (2004).
14. Schneider, D. & Lenski, R.E. Dynamics of insertion sequence elements during experimental evolution of bacteria. *Res. Microbiol.* **155**, 319–327 (2004).
15. Barker, C.S., Pruss, B.M. & Matsumura, P. Increased motility of *Escherichia coli* by insertion sequence element integration into the regulatory region of the *flhD* operon. *J. Bacteriol.* **186**, 7529–7537 (2004).
16. Herring, C.D., Glasner, J.D. & Blattner, F.R. Gene replacement without selection: regulated suppression of amber mutations in *Escherichia coli*. *Gene* **311**, 153–163 (2003).
17. Jensen, K.F. The *Escherichia coli* K-12 “wild types” W3110 and MG1655 have an *rph* frameshift mutation that leads to pyrimidine starvation due to low *pyrE* expression levels. *J. Bacteriol.* **175**, 3401–3407 (1993).
18. Holtman, C.K., Pawlyk, A.C., Meadow, N.D. & Pettigrew, D.W. Reverse genetics of *Escherichia coli* glycerol kinase allosteric regulation and glucose control of glycerol utilization *in vivo*. *J. Bacteriol.* **183**, 3336–3344 (2001).
19. Zwaig, N., Kistler, W.S. & Lin, E.C. Glycerol kinase, the pacemaker for the dissimilation of glycerol in *Escherichia coli*. *J. Bacteriol.* **102**, 753–759 (1970).
20. Ferguson, G.P., Totemeyer, S., MacLean, M.J. & Booth, I.R. Methylglyoxal production in bacteria: suicide or survival? *Arch. Microbiol.* **170**, 209–218 (1998).
21. Saier, M.H.J., Ramseier, T.M. & Reizer, J. Regulation of carbon utilization. in *Escherichia coli and Salmonella*, Vol. 1 (ed. Neidhardt, F.C.) 1325–1343 (ASM Press, Washington, D.C., 1996).
22. Eppler, T., Postma, P., Schutz, A., Volker, U. & Boos, W. Glycerol-3-phosphate-induced catabolite repression in *Escherichia coli*. *J. Bacteriol.* **184**, 3044–3052 (2002).
23. Lawson, C.L. *et al.* Catabolite activator protein: DNA binding and transcription activation. *Curr. Opin. Struct. Biol.* **14**, 10–20 (2004).
24. Ross, P., Hall, L. & Haff, L.A. Quantitative approach to single-nucleotide polymorphism analysis using MALDI-TOF mass spectrometry. *Biotechniques* **29**, 620–629 (2000).
25. Liu, W.Z., Faber, R., Feese, M., Remington, S.J. & Pettigrew, D.W. *Escherichia coli* glycerol kinase: role of a tetramer interface in regulation by fructose 1,6-bisphosphate and phosphotransferase system regulatory protein IIIglc. *Biochemistry* **33**, 10120–10126 (1994).
26. Wang, H. *et al.* The origin of the naked grains of maize. *Nature* **436**, 714–719 (2005).
27. Zeyl, C. The number of mutations selected during adaptation in a laboratory population of *Saccharomyces cerevisiae*. *Genetics* **169**, 1825–1831 (2005).
28. Taubenberger, J.K. *et al.* Characterization of the 1918 influenza virus polymerase genes. *Nature* **437**, 889–893 (2005).
29. Margulies, M. *et al.* Genome sequencing in microfabricated high-density picolitre reactors. *Nature* **437**, 376–380 (2005).
30. Gerrish, P.J. & Lenski, R.E. The fate of competing beneficial mutations in an asexual population. *Genetica* **102–103**, 127–144 (1998).
31. King, T., Ishihama, A., Kori, A. & Ferenci, T. A regulatory trade-off as a source of strain variation in the species *Escherichia coli*. *J. Bacteriol.* **186**, 5614–5620 (2004).
32. Dobrindt, U., Hentschel, U., Kaper, J.B. & Hacker, J. Genome plasticity in pathogenic and nonpathogenic enterobacteria. *Curr. Top. Microbiol. Immunol.* **264**, 157–175 (2002).
33. Miller, B.G. & Raines, R.T. Identifying latent enzyme activities: substrate ambiguity within modern bacterial sugar kinases. *Biochemistry* **43**, 6387–6392 (2004).
34. Janson, C.A. & Cleland, W.W. The kinetic mechanism of glycerokinase. *J. Biol. Chem.* **249**, 2562–2566 (1974).
35. Bansal, A. *et al.* Association testing by DNA pooling: an effective initial screen. *Proc. Natl. Acad. Sci. USA* **99**, 16871–16874 (2002).